$GNTA News

Genenta Science Signs Definitive Agreements With Sòphia High Tech; Genenta Expects To Fund Total Of €6 Million In Two Tranches

Genenta Science Enters Into Binding Offer With Sòphia High Tech For €6M Through Two Reserved Capital Increases, With The Goal Of Reaching Controlling Stake Upon The Achievement Of Defined Performance Milestones

Genenta, Transitioning To Saentra Forge, Pursues Collaboration Opportunities For Biotechnology Platform While Confirming No Active Strategic Partner Talks

Genenta, Transitioning To Saentra Forge, Pursues Collaboration Opportunities For Biotechnology Platform While Confirming No Active Strategic Partner Talks

Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Genenta Science Advances Saentra Forge Rebrand, Bolsters ATC Defense Board With Paolo Salvato Appointment Amid National Security Acquisition Push

Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Genenta Announces Strategic Transformation Into A Biotech, Defense, Aerospace And National Security Industrial Consolidator With Planned Rebrand To Saentra Forge

Genenta Science Provides Update on CEO Ownership

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Genenta Science Announced An Update From Its Ongoing TEM-GBM Study In Newly Diagnosed Glioblastoma Multiforme (GBM) Patients With An Unmethylated MGMT (uMGMT) Gene Promoter

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Genenta Science shares are trading lower after the company announced a $15 million registered direct offering of American Depositary Shares at $3.50 each.

Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism

Reported Sunday, Genenta Prices $15M Registered Direct Offering Of ADSs At $3.50 Each To Support Working Capital And Corporate Growth

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta Science shares are trading higher. The company extended its collaboration with Anemocyte to boost off-the-shelf genetic therapy production.